alas2 Antibody

What is ALAS2 and why is it significant in research?

ALAS2 (Delta-Aminolevulinate Synthase 2) is an erythroid-specific enzyme that catalyzes the first and rate-limiting step in heme biosynthesis. It catalyzes the pyridoxal 5'-phosphate (PLP)-dependent condensation of succinyl-CoA and glycine to form aminolevulinic acid (ALA), with CoA and CO2 as by-products . Unlike ALAS1 which is ubiquitously expressed throughout the body, ALAS2 is specifically expressed in red blood cells .

The significance of ALAS2 in research stems from its critical role in erythropoiesis and its association with several hematological disorders. Mutations in the ALAS2 gene cause X-linked sideroblastic anemia (XLSA), a condition characterized by the presence of ring sideroblasts in the bone marrow . Additionally, deletion/frameshift mutations in the carboxyl-terminal region of ALAS2 can lead to X-linked protoporphyria (XLP) with cutaneous photosensitivity . Recent research has also implicated ALAS2 in oxidative stress responses and ferroptosis, expanding its significance beyond classical heme biosynthesis .

What types of ALAS2 antibodies are available for research applications?

Several types of ALAS2 antibodies are available, each with specific characteristics suitable for different research applications:

When selecting an ALAS2 antibody, researchers should consider the specific isoform they wish to detect, the experimental application, and the species of their samples. Different antibodies may have varying sensitivities and specificities for particular applications or species .

What are the common applications for ALAS2 antibodies?

ALAS2 antibodies are utilized in various experimental applications, each providing unique insights into ALAS2 expression, localization, and function:

• Western Blotting (WB): The most common application, allowing detection and quantification of ALAS2 protein levels. Typical dilutions range from 1:500 to 1:3000, depending on the antibody . Western blotting has been used to demonstrate how H₂O₂ treatment upregulates ALAS2 protein levels and affects ferroptosis-related protein levels .

• Immunoprecipitation (IP): Useful for isolating ALAS2 and its interacting proteins. Select antibodies like the Abcam EPR15112(B) are specifically validated for this application .

• Immunofluorescence (IF)/Immunocytochemistry (ICC): Enables visualization of ALAS2's subcellular localization, particularly its presence in mitochondria. Recommended dilutions typically range from 1:50 to 1:500 .

• ELISA: Provides quantitative measurement of ALAS2 levels in biological samples .

• Flow Cytometry: Allows analysis of ALAS2 expression in individual cells within heterogeneous populations, particularly useful for studying erythroid differentiation .

For optimal results, researchers should follow the specific protocol recommended by the manufacturer of their chosen ALAS2 antibody, as conditions may vary between different antibody products.

How can ALAS2 antibodies be utilized for studying X-linked sideroblastic anemia (XLSA)?

ALAS2 antibodies play a crucial role in studying X-linked sideroblastic anemia (XLSA) through multiple methodological approaches:

• Mutation effect characterization: XLSA results from mutations in the ALAS2 gene that reduce enzymatic activity. At least 61 different ALAS2 mutations have been discovered in 103 separate pan-ethnic XLSA kindreds . Antibodies can be used to assess how these mutations affect protein expression, stability, and localization in cellular models.

• Protein activity correlation: Some XLSA-causing mutations have subtle effects on ALAS2 that are only revealed under specific conditions. Research has shown that certain mutated proteins had decreased activity when assayed in the absence of exogenous pyridoxal phosphate and increased thermosensitivity . Antibodies can help correlate protein levels with enzymatic activity assays.

• Molecular mechanism exploration: In vitro expression of XLSA-associated ALAS2 variants enables detailed investigation of enzymatic dysfunction. For example, certain C-terminal mutations (V562A and M567I) affect enzyme stability and substrate binding without causing gross structural perturbations .

• Therapeutic response monitoring: Many XLSA cases are responsive to vitamin B6 therapy . ALAS2 antibodies can monitor changes in protein expression or localization during treatment, helping to understand the mechanism of therapeutic response.

• Bone marrow analysis: Immunohistochemistry with ALAS2 antibodies can be used to study erythroid precursors in bone marrow samples from XLSA patients, potentially revealing abnormal patterns of expression associated with ring sideroblast formation.

By combining these approaches, researchers can gain comprehensive insights into the molecular pathophysiology of XLSA and potentially identify new therapeutic targets.

What is the role of ALAS2 in oxidative stress and ferroptosis, and how can antibodies help elucidate this function?

Recent research has uncovered an important role for ALAS2 in oxidative stress responses and ferroptosis, extending its known functions beyond heme biosynthesis. ALAS2 antibodies are instrumental in investigating these emerging roles:

• Expression changes during oxidative stress: Studies have shown that H₂O₂ treatment increases MOVAS cells' iron content and oxidative stress while upregulating ALAS2 protein levels . Western blotting with ALAS2 antibodies can quantify these changes and correlate them with cellular responses.

• Protective mechanism investigation: ALAS2 overexpression has been demonstrated to reverse H₂O₂-induced apoptosis and decrease inflammatory cytokine levels . Antibodies confirm successful overexpression and help monitor downstream effects on cellular processes.

• Ferroptosis pathway analysis: ALAS2 antibodies can be used alongside antibodies against ferroptosis-related proteins (NRF2, SLC7A11, GPX4) to track pathway changes and establish the position of ALAS2 in the ferroptosis network .

• GATA1 interaction studies: The knockdown of GATA1 partially reverses the protective mechanism of overexpressed ALAS2 on H₂O₂-induced ferroptosis . Co-immunoprecipitation with ALAS2 antibodies can help elucidate this regulatory relationship.

• Therapeutic target validation: The protective effect of ALAS2 against oxidative stress suggests it could be a potential therapeutic target for conditions involving ferroptosis. Antibodies help validate ALAS2 as a marker and target in these contexts.

This emerging field of research highlights the versatility of ALAS2 antibodies beyond their traditional use in hematological research, positioning them as valuable tools for studying cellular responses to oxidative stress and ferroptosis.

How does the relationship between ALAS2 and GATA1 influence erythropoiesis, and how can antibodies help study this interaction?

The interaction between ALAS2 and GATA1 represents a critical regulatory axis in erythropoiesis, with significant implications for hematological disorders. Antibodies against both proteins enable detailed investigation of this relationship:

• Transcriptional regulation: A novel erythroid-specific enhancer of 130 base pairs in the first intron of the ALAS2 gene contains a GATA-binding site . GATA1 binds to this enhancer to regulate ALAS2 expression, increasing promoter activity 10-15 fold in K562 cells .

• Chromatin Immunoprecipitation (ChIP): GATA1 antibodies can be used for ChIP analysis to confirm binding to the ALAS2 enhancer in vivo. This technique has enabled researchers to examine the GATA1-binding activity of individual GATA elements in the first intron of the ALAS2 gene .

• Electrophoretic Mobility Shift Assay (EMSA): In vitro confirmation of GATA1 binding to ALAS2 enhancer elements can be performed using purified proteins and specific antibodies. This approach has demonstrated that mutations in the GATA-binding site abolish GATA1 binding .

• Clinical relevance: Mutations disrupting the GATA-binding site in the ALAS2 enhancer have been identified in patients with congenital sideroblastic anemia . These mutations abolished enhancer function on ALAS2 promoter activity, highlighting the pathological significance of this interaction.

• Functional interaction in disease processes: GATA1 knockdown partially reverses the protective mechanism of overexpressed ALAS2 on H₂O₂-induced ferroptosis . Antibodies for both proteins allow researchers to monitor their expression levels and correlate them with cellular outcomes.

Understanding this relationship has significant therapeutic implications, as it suggests that modulating GATA1-ALAS2 interactions could potentially address certain forms of sideroblastic anemia and other disorders involving disrupted erythropoiesis.

What are the optimal protocols for using ALAS2 antibodies in Western blotting?

Successful Western blotting with ALAS2 antibodies requires attention to several technical details:

Sample Preparation:

• Use RIPA lysis buffer containing protease and phosphatase inhibitors (1:1,000)

• Quantify protein concentration using a BCA protein assay kit to ensure consistent loading (aim for 2 mg/mL)

• Include positive controls such as K-562 cells, NIH/3T3 cells, or mouse heart tissue

Gel Electrophoresis and Transfer:

• Separate proteins using standard SDS-PAGE protocols

• Transfer to PVDF membrane for optimal protein binding

• Verify transfer efficiency with reversible staining before blocking

Antibody Incubation:

• Block membrane with appropriate buffer (typically 5% non-fat milk or 1% BSA in TBST)

• Dilute primary antibodies according to manufacturer recommendations:

  • Kerafast anti-ALAS2: 1:25,000 in 1% BSA

  • Boster Bio ALAS2 mouse monoclonal: 1:2,000

  • Proteintech rabbit polyclonal: 1:500-1:3,000

• Incubate with primary antibody overnight at 4°C for optimal binding

• Wash thoroughly with TBST (3-5 times, 5-10 minutes each)

• Incubate with appropriate HRP-conjugated secondary antibody (e.g., 1:50,000 anti-rabbit for some applications)

Detection and Analysis:

• Use enhanced chemiluminescence for visualization

• ALAS2 should be detected at approximately 65 kDa

• Some antibodies may detect the protein at slightly different weights (e.g., 59.5 kDa)

• For multiple isoforms, use gradient gels for better resolution

For specialized applications, such as detecting ALAS2 in erythroid precursors or studying specific mutations, optimization of these protocols may be necessary to achieve optimal results.

How to troubleshoot non-specific binding when using ALAS2 antibodies?

Non-specific binding can compromise the interpretation of results when working with ALAS2 antibodies. Here's a systematic approach to troubleshooting this common issue:

Common Causes and Solutions:

• Antibody concentration issues

  • Problem: Too high concentration leads to background; too low gives insufficient signal

  • Solution: Perform titration experiments with different antibody dilutions

  • Method: For Western blotting, try a range from 1:500 to 1:3000 ; for IF/ICC, start at 1:50-1:500

• Cross-reactivity with ALAS1

  • Problem: ALAS1 and ALAS2 share structural similarities despite different tissue expression

  • Solution: Use antibodies specifically validated for ALAS2 vs. ALAS1 discrimination

  • Method: Include controls with known ALAS2-only expressing tissues (erythroid cells) and ALAS1-predominant tissues

• Blocking optimization

  • Problem: Insufficient blocking allows non-specific antibody binding

  • Solution: Optimize blocking conditions and duration

  • Method: 1% BSA has been effectively used for ALAS2 antibodies ; try different blocking agents (BSA, milk, serum)

• Secondary antibody issues

  • Problem: Secondary antibody contributes to background

  • Solution: Increase dilution or try different secondary antibody

  • Method: High dilutions (e.g., 1:50,000) of secondary antibody have been used successfully with some ALAS2 antibodies

Application-Specific Troubleshooting:

• Western Blotting

  • Increase wash stringency (more washes, higher salt concentration)

  • Use freshly prepared buffers

  • If multiple bands appear, validate using ALAS2 knockdown controls

  • Expected molecular weight is ~65 kDa ; bands at significantly different sizes require validation

• Immunofluorescence

  • Include an isotype control antibody

  • Counter-stain with mitochondrial markers to confirm the expected localization pattern of ALAS2

  • Use confocal microscopy for better subcellular resolution

  • Reduce autofluorescence with appropriate quenching methods

• Immunoprecipitation

  • Pre-clear lysates thoroughly

  • Use more stringent wash buffers

  • Compare results with IgG control immunoprecipitation

  • Consider cross-linking antibody to beads to eliminate IgG contamination

Systematic optimization of these parameters can significantly improve the specificity and reliability of ALAS2 antibody applications, ensuring valid and reproducible research outcomes.

What validation methods should be employed to ensure ALAS2 antibody specificity?

Thorough validation of ALAS2 antibodies is essential for generating reliable and reproducible research data. A comprehensive validation approach includes:

• Positive and negative controls

  • Positive controls: K-562 cells, NIH/3T3 cells, mouse brain tissue, mouse heart tissue

  • Negative controls: Non-erythroid cell lines with confirmed absence of ALAS2 expression

  • Knockdown controls: siRNA or CRISPR-mediated ALAS2 depletion to confirm signal specificity

• Cross-reactivity assessment

  • Test for cross-reactivity with ALAS1 using tissues expressing predominantly one isoform

  • Verify specificity using recombinant ALAS2 vs. ALAS1 proteins

  • Compare observed molecular weight (65 kDa) with calculated molecular weight (64.633 kDa)

• Multiple application testing

  • Validate antibody performance across multiple techniques (WB, IHC, ICC, IF, ELISA)

  • Confirm consistent results between different applications

  • Document optimal conditions for each application

• Peptide competition assays

  • Pre-incubate antibody with immunizing peptide to block specific binding

  • Compare signals with and without peptide competition

  • Specific signals should be significantly reduced or eliminated after peptide competition

• Overexpression systems

  • Test antibody in systems overexpressing ALAS2, such as "HEK293T cells transfected with pCMV6-ENTRY ALAS2"

  • Compare signal intensity between overexpression and control conditions

  • Verify correct molecular weight and subcellular localization

• Mass spectrometry validation

  • Perform immunoprecipitation followed by mass spectrometry identification

  • Confirm that the antibody captures ALAS2 and determine what other proteins might co-precipitate

  • This approach provides the gold standard for antibody specificity

• Batch-to-batch consistency

  • Test new lots against previous lots to ensure consistent performance

  • Document lot-specific optimal dilutions and conditions

  • Maintain reference samples for comparative testing

Implementing these validation approaches ensures that experimental findings with ALAS2 antibodies accurately reflect the biology of this important enzyme rather than artifacts of non-specific antibody interactions.